Northern Trust Corp Buys 7,341 Shares of TransMedics Group, Inc. $TMDX

Key Points

• Northern Trust Corp has increased its holdings in TransMedics Group, Inc. by 2.1% in the first quarter, owning 361,963 shares valued at approximately $24.35 million.
• Insider Anil P. Ranganath sold 686 shares of TransMedics stock at an average price of $139.80, marking a 4.69% decrease in their position.
• Analysts have mixed ratings on TransMedics Group, with price targets ranging from $115.00 to $145.00, and a consensus rating of "Moderate Buy" with a target of $123.00.

Northern Trust Corp increased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 2.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 361,963 shares of the company's stock after acquiring an additional 7,341 shares during the quarter. Northern Trust Corp owned about 1.07% of TransMedics Group worth $24,353,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its position in TransMedics Group by 1,565.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock valued at $16,820,000 after buying an additional 253,624 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of TransMedics Group by 1,602.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,359 shares of the company's stock worth $272,000 after buying an additional 4,103 shares during the period. Stifel Financial Corp grew its position in shares of TransMedics Group by 20.8% in the 4th quarter. Stifel Financial Corp now owns 8,968 shares of the company's stock valued at $559,000 after purchasing an additional 1,544 shares during the period. Freestone Grove Partners LP bought a new stake in shares of TransMedics Group during the 4th quarter worth approximately $241,000. Finally, Bellevue Group AG grew its holdings in TransMedics Group by 13.5% in the 4th quarter. Bellevue Group AG now owns 192,718 shares of the company's stock valued at $12,016,000 after buying an additional 22,874 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Insider Transactions at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider directly owned 13,955 shares of the company's stock, valued at $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Trading Down 2.2%

Shares of TransMedics Group stock traded down $2.28 during trading hours on Friday, reaching $101.77. The stock had a trading volume of 252,101 shares, compared to its average volume of 1,303,051. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $169.29. The firm has a 50 day simple moving average of $118.62 and a two-hundred day simple moving average of $103.89. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The firm has a market capitalization of $3.47 billion, a price-to-earnings ratio of 52.48 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. During the same period in the previous year, the firm posted $0.35 EPS. The company's quarterly revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on TMDX shares. Oppenheimer increased their target price on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research report on Tuesday, June 17th. Piper Sandler restated an "overweight" rating and set a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Wall Street Zen downgraded TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday, August 30th. Morgan Stanley lifted their price target on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Finally, Stifel Nicolaus began coverage on TransMedics Group in a report on Thursday. They issued a "hold" rating and a $115.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $122.11.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.